Lupus
![](https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN.jpg)
1 year 9 months ago
Pooled data from AURORA 1 and 2 show that Voclosporin maintained reductions in UPCR vs. control over the 3-yr treatment period in pts with #lupus nephritis
#ACR22 @RheumNow ABST#1653 https://t.co/C4n6Yb8bdC
![](https://pbs.twimg.com/media/FhQQFJ_aAAAp3Ko.jpg)
![](https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3.jpg)
1 year 9 months ago
Nestor et al. HCQ <5mg/kg day assoc increased hospitalisation for SLE flare. aOR 4.41 (95% CI 1.50-12.98) @RheumNow #ACR22 Abstr#1654 https://t.co/I4bTu2DWaR https://t.co/jpOwHUTenk
![](https://pbs.twimg.com/media/FhhzkdQWYAQzogG.jpg)
![](https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN.jpg)
1 year 9 months ago
Are we giving enough HCQ?🤔
Findings from the study of Dr J Nestor show that ⬇️dose HCQ (</= 5mkd or <400mg/day) is associated w/ ⬆️hospitalizations for #lupus (adj. OR 4.41; 3.48)
#ACR22 @RheumNow ABST#1654 @rheumarhyme #ACRBest https://t.co/XCoZgbdOim
![](https://pbs.twimg.com/media/FhhETiyVQAAR3-7.jpg)
For lupus, sedentary lifestyle may be a driving force of disease activity. Today, the final day of ACR, Sarah Patterson, MD from UCSF will present oral abstract #2225 entitled “Physical…
![](https://pbs.twimg.com/profile_images/1007774150000332801/SjLeJk3G.jpg)
1 year 9 months ago
What’s new w #classification for #APS? You don’t have to have 2 positive tests disseminated in time. BUT remember the the labs for anticardiolipin are shockingly variable btwn centres. @RheumNow #ACR22 https://t.co/NTqQ6h7fws
![](https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3.jpg)
1 year 9 months ago
Chen et al. Appendicitis associated increased risk incident SLE in population-based case-control study from Taiwan. HR 2.04 @RheumNow #ACR22 Abstr#1750 https://t.co/L9dTpMdHNP https://t.co/mEHeL6JnuE
![](https://pbs.twimg.com/media/FhNPPyiXoAAycrC.png)
![](https://pbs.twimg.com/profile_images/1322922848810422289/oM4qP9_k.jpg)
1 year 9 months ago
#ACR2022 L07: Telitacicept - anti-BlyS and APRIL in SLE
335 pts P3 52 wk study TEL 160 mg SQ q7d vs PBO
83% SRI4 response in TEL vs 38% PBO (p<0.001)
As early as w4, sustained to w52
Most common AEs: URIs, decr IgG/IgM, injxn site rxn, UTI
@RheumNow #ACRBest https://t.co/UpEwEaonDO
![](https://pbs.twimg.com/media/Fhh3BdlXgAEUtxJ.jpg)
![](https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg)
1 year 9 months ago
A Novel Treatment Response Measurement Tool for Lupus
Dr. Dao discusses abstract 2054 with Dr. Morand at the #ACR22 Convergence. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
https://t.co/iqqyI953Vz https://t.co/taUjTHsrJ2
![](https://pbs.twimg.com/media/FhhyHmVXwAAsYt2.jpg)
![](https://pbs.twimg.com/profile_images/1373134367841681415/ThbCOjtj.jpg)
1 year 9 months ago
Even young SLE patients are still at high risk of severe COVID:
- in general pop, age is key factor
- in SLE, risk is high across age groups (maybe due to both meds & disease)
- vaccination makes a big diff but SLE pts still at high risk
ABST1591 @CCalabreseDO #ACR22 @RheumNow https://t.co/ra1F79ITn3
![](https://pbs.twimg.com/media/FhhueB2UAAAhMjL.jpg)
![](https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3.jpg)
1 year 9 months ago
Wu et al Phase 3 RCT of Telitacicept (targets BlyS and APRIL) in SLE. Primary endpoint met at week 52! SRI(4) 67% vs 33% or 83% vs 38% (P<0.001 for both) depending on how you want to slice it. @RheumNow #ACR22 Abstr#L07 https://t.co/nnKr4AU8Jk https://t.co/9BVF6OljFQ
![](https://pbs.twimg.com/media/FhhYfAZWQAct2SD.png)